Prelude Therapeutics PRLD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Prelude Therapeutics (PRLD) Core Market Data and Business Metrics
Latest Closing Price
$0.7872Price-Earnings Ratio
-0.47Total Outstanding Shares
55.16 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
175 Innovation Boulevard, Wilmington, DE, 19805
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 171,181 Shares | 13.16 | 3/14/2025 | 2,252,233 Shares |
| 169,072 Shares | 12.78 | 2/28/2025 | 2,160,583 Shares |
| 219,487 Shares | 14.14 | 2/14/2025 | 3,103,542 Shares |
| 254,613 Shares | 12.37 | 1/31/2025 | 3,149,039 Shares |
| 273,909 Shares | 11.38 | 1/15/2025 | 3,116,988 Shares |
| 1,015,062 Shares | 3.33 | 12/31/2024 | 3,381,616 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-120,000 |
| Net Cash Flow From Investing Activities | $90.19 Million |
| Net Cash Flow From Operating Activities | $-102.89 Million |
| Net Cash Flow From Financing Activities | $-120,000 |
| Net Cash Flow From Investing Activities, Continuing | $90.19 Million |
| Net Cash Flow | $-12.82 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-127.17 Million |
| Costs And Expenses | $134.17 Million |
| Research and Development | $118.00 Million |
| Net Income/Loss | $-127.17 Million |
| Net Income/Loss Attributable To Parent | $-127.17 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-127.36 Million |
| Comprehensive Income/Loss | $-127.36 Million |
| Other Comprehensive Income/Loss | $-188,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $18.41 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Liabilities And Equity | $175.51 Million |
| Equity | $131.46 Million |
| Assets | $175.51 Million |
| Equity Attributable To Parent | $131.46 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||